APO Research
Talk to an analyst

APO RESEARCH · REPORT

Assisted Reproduction Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Assisted Reproduction Drug Market Analysis and Forecast 2026-2032

30 December 2025191 pages

Choose your research edition.

Industry ResearchAssisted Reproduction Drug Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Assisted Reproduction Drug Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Assisted Reproduction Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Assisted Reproduction Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Assisted Reproduction Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Assisted Reproduction Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Assisted Reproduction Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Assisted Reproduction Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Assisted Reproduction Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Assisted Reproduction Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Assisted Reproduction Drug include Ipsen Pharma Biotech, Zhejiang Xianju Pharmaceutical Co., Ltd., Solvay Pharma, Shanghai First Biochemical Pharmaceutical Co. LTD, Merck Sharp & Dohme, Merck Serono, Livzon Group and GenSci, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Assisted Reproduction Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Assisted Reproduction Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Assisted Reproduction Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Assisted Reproduction Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Assisted Reproduction Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Assisted Reproduction Drug revenue, projected growth trends, production technology, application and end-user industry.

Assisted Reproduction Drug Segment by Company

Ipsen Pharma Biotech

Zhejiang Xianju Pharmaceutical Co., Ltd.

Solvay Pharma

Shanghai First Biochemical Pharmaceutical Co. LTD

Merck Sharp & Dohme

Merck Serono

Livzon Group

GenSci

Assisted Reproduction Drug Segment by Type

Progestogen Hormone

Human Choroinic Gonadotrophin

Gonadotropin Releasing Hormone

Follicle-stimulating Hormone

Assisted Reproduction Drug Segment by Application

Controlled Ovarian Hyperstimulation

luteal Support

Down Regultion

Induced Ovulation

Assisted Reproduction Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Assisted Reproduction Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Assisted Reproduction Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Assisted Reproduction Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Assisted Reproduction Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Assisted Reproduction Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Assisted Reproduction Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Assisted Reproduction Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Progestogen Hormone Major Player Table 3. Human Choroinic Gonadotrophin Major Player Table 4. Gonadotropin Releasing Hormone Major Player Table 5. Follicle-stimulating Hormone Major Player Table 6. Global Assisted Reproduction Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Controlled Ovarian Hyperstimulation Major Player Table 8. luteal Support Major Player Table 9. Down Regultion Major Player Table 10. Induced Ovulation Major Player Table 11. Assisted Reproduction Drug Industry Trends Table 12. Assisted Reproduction Drug Industry Drivers Table 13. Assisted Reproduction Drug Industry Opportunities and Challenges Table 14. Assisted Reproduction Drug Industry Restraints Table 15. Global Assisted Reproduction Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Assisted Reproduction Drug Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Assisted Reproduction Drug Market Share by Region (2021-2026) Table 18. Global Assisted Reproduction Drug Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Assisted Reproduction Drug Market Share by Region (2027-2032) Table 20. Global Assisted Reproduction Drug Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Assisted Reproduction Drug Revenue Market Share by Players (2021-2026) Table 22. Global Assisted Reproduction Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Assisted Reproduction Drug Key Players Headquarters & Area Served Table 24. Global Assisted Reproduction Drug Players, Product Type & Application Table 25. Global Assisted Reproduction Drug Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Assisted Reproduction Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Assisted Reproduction Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Assisted Reproduction Drug Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Assisted Reproduction Drug Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Assisted Reproduction Drug Revenue Market Share by Type (2021-2026) Table 32. Global Assisted Reproduction Drug Revenue Market Share by Type (2027-2032) Table 33. Global Assisted Reproduction Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Assisted Reproduction Drug Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Assisted Reproduction Drug Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Assisted Reproduction Drug Revenue Market Share by Application (2021-2026) Table 37. Global Assisted Reproduction Drug Revenue Market Share by Application (2027-2032) Table 38. Ipsen Pharma Biotech Company Information Table 39. Ipsen Pharma Biotech Business Overview Table 40. Ipsen Pharma Biotech Assisted Reproduction Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Ipsen Pharma Biotech Assisted Reproduction Drug Product Portfolio Table 42. Ipsen Pharma Biotech Recent Development Table 43. Zhejiang Xianju Pharmaceutical Co., Ltd. Company Information Table 44. Zhejiang Xianju Pharmaceutical Co., Ltd. Business Overview Table 45. Zhejiang Xianju Pharmaceutical Co., Ltd. Assisted Reproduction Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Zhejiang Xianju Pharmaceutical Co., Ltd. Assisted Reproduction Drug Product Portfolio Table 47. Zhejiang Xianju Pharmaceutical Co., Ltd. Recent Development Table 48. Solvay Pharma Company Information Table 49. Solvay Pharma Business Overview Table 50. Solvay Pharma Assisted Reproduction Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Solvay Pharma Assisted Reproduction Drug Product Portfolio Table 52. Solvay Pharma Recent Development Table 53. Shanghai First Biochemical Pharmaceutical Co. LTD Company Information Table 54. Shanghai First Biochemical Pharmaceutical Co. LTD Business Overview Table 55. Shanghai First Biochemical Pharmaceutical Co. LTD Assisted Reproduction Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Shanghai First Biochemical Pharmaceutical Co. LTD Assisted Reproduction Drug Product Portfolio Table 57. Shanghai First Biochemical Pharmaceutical Co. LTD Recent Development Table 58. Merck Sharp & Dohme Company Information Table 59. Merck Sharp & Dohme Business Overview Table 60. Merck Sharp & Dohme Assisted Reproduction Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Merck Sharp & Dohme Assisted Reproduction Drug Product Portfolio Table 62. Merck Sharp & Dohme Recent Development Table 63. Merck Serono Company Information Table 64. Merck Serono Business Overview Table 65. Merck Serono Assisted Reproduction Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Merck Serono Assisted Reproduction Drug Product Portfolio Table 67. Merck Serono Recent Development Table 68. Livzon Group Company Information Table 69. Livzon Group Business Overview Table 70. Livzon Group Assisted Reproduction Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Livzon Group Assisted Reproduction Drug Product Portfolio Table 72. Livzon Group Recent Development Table 73. GenSci Company Information Table 74. GenSci Business Overview Table 75. GenSci Assisted Reproduction Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. GenSci Assisted Reproduction Drug Product Portfolio Table 77. GenSci Recent Development Table 78. North America Assisted Reproduction Drug Revenue by Type (2021-2026) & (US$ Million) Table 79. North America Assisted Reproduction Drug Revenue by Type (2027-2032) & (US$ Million) Table 80. North America Assisted Reproduction Drug Revenue by Application (2021-2026) & (US$ Million) Table 81. North America Assisted Reproduction Drug Revenue by Application (2027-2032) & (US$ Million) Table 82. North America Assisted Reproduction Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 83. North America Assisted Reproduction Drug Revenue by Country (2021-2026) & (US$ Million) Table 84. North America Assisted Reproduction Drug Revenue by Country (US$ Million) & (2027-2032) Table 85. Europe Assisted Reproduction Drug Revenue by Type (2021-2026) & (US$ Million) Table 86. Europe Assisted Reproduction Drug Revenue by Type (2027-2032) & (US$ Million) Table 87. Europe Assisted Reproduction Drug Revenue by Application (2021-2026) & (US$ Million) Table 88. Europe Assisted Reproduction Drug Revenue by Application (2027-2032) & (US$ Million) Table 89. Europe Assisted Reproduction Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. Europe Assisted Reproduction Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. Europe Assisted Reproduction Drug Revenue by Country (US$ Million) & (2027-2032) Table 92. China Assisted Reproduction Drug Revenue by Type (2021-2026) & (US$ Million) Table 93. China Assisted Reproduction Drug Revenue by Type (2027-2032) & (US$ Million) Table 94. China Assisted Reproduction Drug Revenue by Application (2021-2026) & (US$ Million) Table 95. China Assisted Reproduction Drug Revenue by Application (2027-2032) & (US$ Million) Table 96. Asia Assisted Reproduction Drug Revenue by Type (2021-2026) & (US$ Million) Table 97. Asia Assisted Reproduction Drug Revenue by Type (2027-2032) & (US$ Million) Table 98. Asia Assisted Reproduction Drug Revenue by Application (2021-2026) & (US$ Million) Table 99. Asia Assisted Reproduction Drug Revenue by Application (2027-2032) & (US$ Million) Table 100. Asia Assisted Reproduction Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 101. Asia Assisted Reproduction Drug Revenue by Region (US$ Million) & (2021-2026) Table 102. Asia Assisted Reproduction Drug Revenue by Region (US$ Million) & (2027-2032) Table 103. SAMEA Assisted Reproduction Drug Revenue by Type (2021-2026) & (US$ Million) Table 104. SAMEA Assisted Reproduction Drug Revenue by Type (2027-2032) & (US$ Million) Table 105. SAMEA Assisted Reproduction Drug Revenue by Application (2021-2026) & (US$ Million) Table 106. SAMEA Assisted Reproduction Drug Revenue by Application (2027-2032) & (US$ Million) Table 107. SAMEA Assisted Reproduction Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. SAMEA Assisted Reproduction Drug Revenue by Country (2021-2026) & (US$ Million) Table 109. SAMEA Assisted Reproduction Drug Revenue by Country (US$ Million) & (2027-2032) Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Assisted Reproduction Drug Image Figure 2. Global Assisted Reproduction Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Assisted Reproduction Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Progestogen Hormone Image Figure 5. Human Choroinic Gonadotrophin Image Figure 6. Gonadotropin Releasing Hormone Image Figure 7. Follicle-stimulating Hormone Image Figure 8. Global Assisted Reproduction Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Assisted Reproduction Drug Market Size Share 2021 VS 2025 VS 2032 Figure 10. Controlled Ovarian Hyperstimulation Image Figure 11. luteal Support Image Figure 12. Down Regultion Image Figure 13. Induced Ovulation Image Figure 14. Global Assisted Reproduction Drug Market Size (US$ Million) & (2021-2032) Figure 15. Global Assisted Reproduction Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Assisted Reproduction Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Assisted Reproduction Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Assisted Reproduction Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Assisted Reproduction Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Assisted Reproduction Drug Revenue Market Share by Type (2021-2032) Figure 22. Global Assisted Reproduction Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Assisted Reproduction Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Assisted Reproduction Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Assisted Reproduction Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Assisted Reproduction Drug Revenue Share by Type (2021-2032) Figure 27. North America Assisted Reproduction Drug Revenue Share by Application (2021-2032) Figure 28. North America Assisted Reproduction Drug Revenue Share by Country (2021-2032) Figure 29. United States Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Assisted Reproduction Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Assisted Reproduction Drug Revenue Share by Type (2021-2032) Figure 34. Europe Assisted Reproduction Drug Revenue Share by Application (2021-2032) Figure 35. Europe Assisted Reproduction Drug Revenue Share by Country (2021-2032) Figure 36. Germany Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Assisted Reproduction Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Assisted Reproduction Drug Revenue Share by Type (2021-2032) Figure 46. China Assisted Reproduction Drug Revenue Share by Application (2021-2032) Figure 47. Asia Assisted Reproduction Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Assisted Reproduction Drug Revenue Share by Type (2021-2032) Figure 49. Asia Assisted Reproduction Drug Revenue Share by Application (2021-2032) Figure 50. Asia Assisted Reproduction Drug Revenue Share by Region (2021-2032) Figure 51. Japan Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Assisted Reproduction Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Assisted Reproduction Drug Revenue Share by Type (2021-2032) Figure 59. SAMEA Assisted Reproduction Drug Revenue Share by Application (2021-2032) Figure 60. SAMEA Assisted Reproduction Drug Revenue Share by Country (2021-2032) Figure 61. Brazil Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Assisted Reproduction Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Progestogen Hormone
  • Human Choroinic Gonadotrophin
  • Gonadotropin Releasing Hormone
  • Follicle-stimulating Hormone
Applications
  • Controlled Ovarian Hyperstimulation
  • luteal Support
  • Down Regultion
  • Induced Ovulation
Companies covered
  • Ipsen Pharma Biotech
  • Zhejiang Xianju Pharmaceutical Co., Ltd.
  • Solvay Pharma
  • Shanghai First Biochemical Pharmaceutical Co. LTD
  • Merck Sharp & Dohme
  • Merck Serono
  • Livzon Group
  • GenSci

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Assisted Reproduction Drug Market by Type
  3. 1.2.1 Global Assisted Reproduction Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Progestogen Hormone
  5. 1.2.3 Human Choroinic Gonadotrophin
  6. 1.2.4 Gonadotropin Releasing Hormone
  7. 1.2.5 Follicle-stimulating Hormone
  8. 1.3 Assisted Reproduction Drug Market by Application
  9. 1.3.1 Global Assisted Reproduction Drug Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Controlled Ovarian Hyperstimulation
  11. 1.3.3 luteal Support
  12. 1.3.4 Down Regultion
  13. 1.3.5 Induced Ovulation
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Assisted Reproduction Drug Market Dynamics
  1. 2.1 Assisted Reproduction Drug Industry Trends
  2. 2.2 Assisted Reproduction Drug Industry Drivers
  3. 2.3 Assisted Reproduction Drug Industry Opportunities and Challenges
  4. 2.4 Assisted Reproduction Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Assisted Reproduction Drug Market Perspective (2021-2032)
  2. 3.2 Global Assisted Reproduction Drug Growth Trends by Region
  3. 3.2.1 Global Assisted Reproduction Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Assisted Reproduction Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Assisted Reproduction Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Assisted Reproduction Drug Revenue by Players
  2. 4.1.1 Global Assisted Reproduction Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Assisted Reproduction Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Assisted Reproduction Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Assisted Reproduction Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Assisted Reproduction Drug Key Players Headquarters & Area Served
  7. 4.4 Global Assisted Reproduction Drug Players, Product Type & Application
  8. 4.5 Global Assisted Reproduction Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Assisted Reproduction Drug Market CR5 and HHI
  11. 4.6.3 2025 Assisted Reproduction Drug Tier 1, Tier 2, and Tier 3
5 Assisted Reproduction Drug Market Size by Type
  1. 5.1 Global Assisted Reproduction Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Assisted Reproduction Drug Revenue by Type (2021-2032)
  3. 5.3 Global Assisted Reproduction Drug Revenue Market Share by Type (2021-2032)
6 Assisted Reproduction Drug Market Size by Application
  1. 6.1 Global Assisted Reproduction Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Assisted Reproduction Drug Revenue by Application (2021-2032)
  3. 6.3 Global Assisted Reproduction Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Ipsen Pharma Biotech
  2. 7.1.1 Ipsen Pharma Biotech Company Information
  3. 7.1.2 Ipsen Pharma Biotech Business Overview
  4. 7.1.3 Ipsen Pharma Biotech Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Ipsen Pharma Biotech Assisted Reproduction Drug Product Portfolio
  6. 7.1.5 Ipsen Pharma Biotech Recent Developments
  7. 7.2 Zhejiang Xianju Pharmaceutical Co., Ltd.
  8. 7.2.1 Zhejiang Xianju Pharmaceutical Co., Ltd. Company Information
  9. 7.2.2 Zhejiang Xianju Pharmaceutical Co., Ltd. Business Overview
  10. 7.2.3 Zhejiang Xianju Pharmaceutical Co., Ltd. Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Zhejiang Xianju Pharmaceutical Co., Ltd. Assisted Reproduction Drug Product Portfolio
  12. 7.2.5 Zhejiang Xianju Pharmaceutical Co., Ltd. Recent Developments
  13. 7.3 Solvay Pharma
  14. 7.3.1 Solvay Pharma Company Information
  15. 7.3.2 Solvay Pharma Business Overview
  16. 7.3.3 Solvay Pharma Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Solvay Pharma Assisted Reproduction Drug Product Portfolio
  18. 7.3.5 Solvay Pharma Recent Developments
  19. 7.4 Shanghai First Biochemical Pharmaceutical Co. LTD
  20. 7.4.1 Shanghai First Biochemical Pharmaceutical Co. LTD Company Information
  21. 7.4.2 Shanghai First Biochemical Pharmaceutical Co. LTD Business Overview
  22. 7.4.3 Shanghai First Biochemical Pharmaceutical Co. LTD Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Shanghai First Biochemical Pharmaceutical Co. LTD Assisted Reproduction Drug Product Portfolio
  24. 7.4.5 Shanghai First Biochemical Pharmaceutical Co. LTD Recent Developments
  25. 7.5 Merck Sharp & Dohme
  26. 7.5.1 Merck Sharp & Dohme Company Information
  27. 7.5.2 Merck Sharp & Dohme Business Overview
  28. 7.5.3 Merck Sharp & Dohme Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Merck Sharp & Dohme Assisted Reproduction Drug Product Portfolio
  30. 7.5.5 Merck Sharp & Dohme Recent Developments
  31. 7.6 Merck Serono
  32. 7.6.1 Merck Serono Company Information
  33. 7.6.2 Merck Serono Business Overview
  34. 7.6.3 Merck Serono Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Merck Serono Assisted Reproduction Drug Product Portfolio
  36. 7.6.5 Merck Serono Recent Developments
  37. 7.7 Livzon Group
  38. 7.7.1 Livzon Group Company Information
  39. 7.7.2 Livzon Group Business Overview
  40. 7.7.3 Livzon Group Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Livzon Group Assisted Reproduction Drug Product Portfolio
  42. 7.7.5 Livzon Group Recent Developments
  43. 7.8 GenSci
  44. 7.8.1 GenSci Company Information
  45. 7.8.2 GenSci Business Overview
  46. 7.8.3 GenSci Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 GenSci Assisted Reproduction Drug Product Portfolio
  48. 7.8.5 GenSci Recent Developments
8 North America
  1. 8.1 North America Assisted Reproduction Drug Revenue (2021-2032)
  2. 8.2 North America Assisted Reproduction Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Assisted Reproduction Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Assisted Reproduction Drug Revenue by Type (2027-2032)
  5. 8.3 North America Assisted Reproduction Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Assisted Reproduction Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Assisted Reproduction Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Assisted Reproduction Drug Revenue by Application (2027-2032)
  9. 8.5 North America Assisted Reproduction Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Assisted Reproduction Drug Revenue by Country
  11. 8.6.1 North America Assisted Reproduction Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Assisted Reproduction Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Assisted Reproduction Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Assisted Reproduction Drug Revenue (2021-2032)
  2. 9.2 Europe Assisted Reproduction Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Assisted Reproduction Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Assisted Reproduction Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Assisted Reproduction Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Assisted Reproduction Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Assisted Reproduction Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Assisted Reproduction Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Assisted Reproduction Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Assisted Reproduction Drug Revenue by Country
  11. 9.6.1 Europe Assisted Reproduction Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Assisted Reproduction Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Assisted Reproduction Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Assisted Reproduction Drug Revenue (2021-2032)
  2. 10.2 China Assisted Reproduction Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Assisted Reproduction Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Assisted Reproduction Drug Revenue by Type (2027-2032)
  5. 10.3 China Assisted Reproduction Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Assisted Reproduction Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Assisted Reproduction Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Assisted Reproduction Drug Revenue by Application (2027-2032)
  9. 10.5 China Assisted Reproduction Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Assisted Reproduction Drug Revenue (2021-2032)
  2. 11.2 Asia Assisted Reproduction Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Assisted Reproduction Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Assisted Reproduction Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Assisted Reproduction Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Assisted Reproduction Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Assisted Reproduction Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Assisted Reproduction Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Assisted Reproduction Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Assisted Reproduction Drug Revenue by Country
  11. 11.6.1 Asia Assisted Reproduction Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Assisted Reproduction Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Assisted Reproduction Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Assisted Reproduction Drug Revenue (2021-2032)
  2. 12.2 SAMEA Assisted Reproduction Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Assisted Reproduction Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Assisted Reproduction Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Assisted Reproduction Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Assisted Reproduction Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Assisted Reproduction Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Assisted Reproduction Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Assisted Reproduction Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Assisted Reproduction Drug Revenue by Country
  11. 12.6.1 SAMEA Assisted Reproduction Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Assisted Reproduction Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Assisted Reproduction Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst